References
- Shorts L, Weiss JM, Lee JK, Welniak LA, Subleski J, Back T, Murphy WJ, Wiltrout RH. Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. J Immunol 2006; 176 (11):6543-52; PMID:16709811; http://dx.doi.org/10.4049/jimmunol.176.11.6543
- Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH Young LS. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000; 20 (15):5503-15; PMID:10891490; http://dx.doi.org/10.1128/MCB.20.15.5503-5515.2000
- Weiss JM, Gregory Alvord W, Quinones OA, Stauffer JK, Wiltrout RH. CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8 T cell frequency and patient survival. Hum Immunol 2014; 75 (7):614-620; PMID:24801648; http://dx.doi.org/10.1016/j.humimm.2014.04.018
- Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013; 19 (5):1035-43; PMID:23460534; http://dx.doi.org/10.1158/1078-0432.CCR-12-2064
- Melter M, Reinders ME, Sho M, Pal S, Geehan C, Denton MD Mukhopadhyay D, Briscoe DM. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 2000; 96 (12):3801-8; PMID:11090063
- DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010; 1183:38-57; PMID:20146707; http://dx.doi.org/10.1111/j.1749-6632.2009.05137.x
- Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, et al. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A 2009; 106 (46):19455-60; PMID:19892741; http://dx.doi.org/10.1073/pnas.0909474106
- Weiss JM, Ridnour LA, Back T, Hussain SP, He P, Maciag AE, Keefer LK, Murphy WJ, Harris CC, Wink DA, et al. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med 2010; 207 (11):2455-67; PMID:20921282; http://dx.doi.org/10.1084/jem.20100670
- Jiang Q, Weiss JM, Back T, Chan T, Ortaldo JR, Guichard S, Wiltrout RH. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res 2011; 71 (12):4074-84; PMID:21540234; http://dx.doi.org/10.1158/0008-5472.CAN-10-3968
- Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H Sayers TJ, Murphy WJ, Wiltrout RH. Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2/alphaCD40 Therapy. J Immunol 2014; 192 (12):5821-9; PMID:24808361; http://dx.doi.org/10.4049/jimmunol.1400404